Skip to main content
SpringerLink
Log in

Clinical Pharmacokinetics of Oxaprozin

  • Review Articles
  • Drug Disposition
  • Published:
Clinical Pharmacokinetics Aims and scope Submit manuscript

Abstract

Oxaprozin is a nonsteroidal anti-inflammatory drug which reaches peak plasma concentrations 2 to 6 hours after oral administration. Oxaprozin binds extensively, in a concentration-dependent manner, to plasma albumin. The area under the plasma concentration-time curve (AUC) of oxaprozin is linearly proportional to the dose for oral doses up to 1200mg. At doses greater than 1200mg there is an increase in the unbound fraction of drug, leading to an increased clearance and volume of distribution (Vd) of total oxaprozin. Accumulation of the drug at steady state is between 40 and 58% lower than predicted by single dose data.

After administration of multiple doses, the apparent oral clearance (CL/F) and Vd of total oxaprozin increased while those of the unbound drug decreased significantly. Substantial concentrations of oxaprozin are attained in synovial fluid, which is a proposed site of action for nonsteroidal anti-inflammatory drugs. Relationships between total plasma, unbound plasma and synovial concentrations, and therapeutic and toxicological effects have yet to be established.

Oxaprozin is eliminated following biotransformation to glucuroconjugated metabolites which are excreted in urine and bile, with little drug being eliminated unchanged. Two hydroxylated metabolites have been shown to possess antiinflammatory activity.

Hepatic disease and rheumatoid arthritis do not significantly alter the disposition of oxaprozin. Patients with renal impairment demonstrate an increase in unbound plasma concentrations of oxaprozin. A significant drug interaction has been demonstrated between oxaprozin and aspirin (acetylsalicylic acid).

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Lewis AJ, Carlson RP, Chang J, et al. The pharmacological profile of oxaprozin, an anti-inflammatory and analgesic agent with low gastrointestinal toxicity. Curr Ther Res 1983; 34: 777–94.

    CAS  Google Scholar 

  2. Goto J, Muramatsu M, Hosoda K, et al. The inhibitory effect of oxaprozin, a new non-steroidal anti-inflammatory drug, on platelet aggregation. Folia Pharmacol Jpn 1984; 83: 395–400.

    Article  CAS  Google Scholar 

  3. Kawai S, Nishida S, Kato M, et al. Comparison of cyclooxygenase-1 and -2 inhibitory activities of various nonsteroidal anti-inflammatory drugs using human platelets and synovial cells. Eur J Pharmacol 1998; 347: 87–94.

    Article  PubMed  CAS  Google Scholar 

  4. Todd PA, Brogden RN. Oxaprozin: a preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic activity. Drugs 1986; 32: 291–312.

    Article  PubMed  CAS  Google Scholar 

  5. Ingrish G, Rietschel RL. Oxaprozin-induced pseudoporphyria. Arch Dermatol 1996; 132: 1519–20.

    Article  PubMed  CAS  Google Scholar 

  6. Miller LG. Oxaprozin: a once-daily nonsteroidal anti-inflammatory drug. Clin Pharm 1992; 11: 591–603.

    PubMed  CAS  Google Scholar 

  7. McHugh SL, Kirkman SK, Knowles JA. Macro- and micromethods for high-performance liquid chromatographic analysis of oxaprozin in plasma. J Pharm Sci 1980; 69 (7): 794–6.

    Article  PubMed  CAS  Google Scholar 

  8. Matlis R, Greenblatt DJ. Rapid high-performance liquid chromatographic analysis of oxaprozin, a non-steroidal anti-inflammatory agent. J Chromatogr 1984; 310: 445–9.

    Article  PubMed  CAS  Google Scholar 

  9. Pierce DM. Selection of solvents for thin-layer chromatography by means of a simple ranking system based on dielectric constants. Xenobiotica 1981; 11 (12): 857–62.

    Article  PubMed  CAS  Google Scholar 

  10. Abadi M, Solomon HM. Detection of tolmetin and oxaprozin by a GC/MS method for barbiturates [letter. J Anal Toxicol 1994; 18: 62.

    PubMed  CAS  Google Scholar 

  11. Camara PD, Audette L, Velletri K, et al. False-positive immunoassay results for urine benzodiazepines in patients receiving oxaprozin (Daypro™). Clin Chem 1995; 41 (1): 115–6.

    PubMed  CAS  Google Scholar 

  12. Matuch-Hite T, Jones P, Moriarity J. Interference of oxaprozin with benzodiazepines via enzyme immunoassay technique. J Anal Toxicol 1995; 19: 130.

    PubMed  CAS  Google Scholar 

  13. Pulini M. False-positive benzodiazepine urine test due to oxaprozin. JAMA 1995; 283 (24): 1905–6.

    Article  Google Scholar 

  14. Fraser AD, Howell P. Oxaprozin cross-reactivity in three commercial immunoassays for benzodiazepines in urine. J Anal Toxicol 1998; 22: 50–4.

    PubMed  CAS  Google Scholar 

  15. Patel T, Radomski KM, Chandler MHH. Assay interaction between oxaprozin and phenytoin [letter. Ann Pharmacother 1996; 31: 254.

    Google Scholar 

  16. Datta P. Oxaprozin and 5-(p-hydroxyphenyl)-5-phenylhydantoin interference in phenytoin immmunoassays. Clin Chem 1997; 43 (8): 1468–9.

    PubMed  CAS  Google Scholar 

  17. Audet PR, Knowles JA, Troy SM, et al. Effect of chronic renal failure on oxaprozin multiple-dose pharmacokinetics. Clin Pharmacol Ther 1988; 44: 303–9.

    Article  PubMed  CAS  Google Scholar 

  18. Chiang ST, Morrison G, Knowles JA, et al. Oxaprozin disposition in renal disease. Clin Pharmacol Ther 1982; 31 (4): 509–15.

    Article  PubMed  CAS  Google Scholar 

  19. Chiang ST, Lasseter KC, Fluck ER, et al. Oxaprozin dose proportionality. J Clin Pharmacol 1984; 24: 515–22.

    PubMed  CAS  Google Scholar 

  20. Chiang ST, Knowles JA, Hubsher JA, et al. Effects of food on oxaprozin bioavailability. J Clin Pharmacol 1984; 24: 381–5.

    PubMed  CAS  Google Scholar 

  21. Greenblatt DJ, Matlis R, Scavone JM, et al. Oxaprozin pharmacokinetics in the elderly. Br J Clin Pharmacol 1985; 19: 373–8.

    Article  PubMed  CAS  Google Scholar 

  22. Janssen FW, Jusko WJ, Chiang ST, et al. Metabolism and kinetics of oxaprozin in normal subjects. Clin Pharm Ther 1980; 27 (3): 352–62.

    Article  CAS  Google Scholar 

  23. Janssen FW, Chiang ST, Walker BR, et al. Disposition of oxaprozin in healthy subjects and certain disease states. Curr Ther Res 1984; 35 (3): 363–76.

    CAS  Google Scholar 

  24. Kahn SB, Hubsher JA. Effects of oxaprozin alone or in combination with aspirin on hemostasis and plasma protein binding. J Clin Pharmacol 1983; 23: 139–46.

    PubMed  CAS  Google Scholar 

  25. Karim A. Inverse nonlinear pharmacokinetics of total and protein unbound drug (oxaprozin): clinical and pharmacokinetic implications. J Clin Pharmacol 1996; 36: 985–97.

    Article  PubMed  CAS  Google Scholar 

  26. Karim A, Noveck R, McMahon FG, et al. Oxaprozin and piroxicam, non-steroidal antiinflammatory drugs with long half-lives: effect of protein-binding differences on steadystate pharmacokinetics. J Clin Pharmacol 1997; 37: 267–78.

    PubMed  CAS  Google Scholar 

  27. Ochs HR. Oxaprozin pharmacokinetics in patients with congestive heart failure. Arzneimittel Forschung 1986; 36 (2): 1837–40.

    PubMed  CAS  Google Scholar 

  28. Scavone JM, Greenblatt DJ, Matlis R, et al. Interaction of oxaprozin with acetaminophen, cimetidine, and ranitidine. Eur J Clin Pharmacol 1986; 31: 371–4.

    Article  PubMed  CAS  Google Scholar 

  29. Scavone JM, Ochs HR, Greenblatt DJ, et al. Pharmacokinetics of oxaprozin in women receiving conjugated estrogen. Eur J Clin Pharmacol 1988; 35: 105–8.

    Article  PubMed  CAS  Google Scholar 

  30. Verburg-Ochs B, Ochs HR, Greenblatt DJ. Oxaprozin kinetics in congestive heart failure [abstract. Clin Pharmacol Ther 1985; 37: 235.

    Google Scholar 

  31. Suwa T, Urano H, Tsuji A. Pharmacokinetics of oxaprozin after multiple doses. Yakugaku Zasshi 1987; 107 (6): 440–8.

    PubMed  CAS  Google Scholar 

  32. Namiki N, Yokoyama H, Fukuda M, et al. Studies on improvement of pharmaceutical preparations prescribed in hospitals: VI. Oxaprozin nasal spray. Drug Des Deliv 1988; 2: 311–21.

    PubMed  CAS  Google Scholar 

  33. Davies NM. Clinical pharmacokinetics of flurbiprofen and its enantiomers. Clin Pharmacokinet 1995; 28 (2): 100–14.

    Article  PubMed  CAS  Google Scholar 

  34. Davies NM. Clinical pharmacokinetics of tiaprofenic acid and its enantiomers. Clin Pharmacokinet 1996; 31 (5): 331–47.

    Article  PubMed  CAS  Google Scholar 

  35. Davies NM, Anderson KE. Clinical pharmacokinetics of naproxen. Clin Pharmacokinet 1997; 32 (4): 321–5.

    Article  Google Scholar 

  36. Davies NM. Clinical pharmacokinetics of ibuprofen: the first 30 years. Clin Pharmacokinet 1998; 34 (2): 101–54.

    Article  PubMed  CAS  Google Scholar 

  37. Aubry A-F, Markoglou N, Adams MH, et al. The effect of coadministered drugs on oxaprozin binding to human serum albumin. J Pharm Pharmacol 1995; 47: 937–44.

    Article  PubMed  CAS  Google Scholar 

  38. Homon CA, Fluck ER, Janssen FW, et al. Protein binding and clearance of oxaprozin, a highly bound anti-inflammatory agent. Agents Actions 1982; 12 (1/2): 211–5.

    Article  PubMed  CAS  Google Scholar 

  39. Kurowski M, Thabe H. The transynovial distribution of oxaprozin. Agents Actions 1989; 27 (3/4): 458–60.

    Article  PubMed  CAS  Google Scholar 

  40. Hale VG, Bashaw ED, Miller LG. Pharmacokinetics of oxaprozin [letter. Clin Pharmacokinet 1993; 12: 255–6.

    CAS  Google Scholar 

  41. Morrison G, Ponzio D, Rogers SI, et al. The steady-state pharmacokinetics of oxaprozin in patients undergoing hemodialysis [abstract. Clin Res 1985; 33: 286.

    Google Scholar 

  42. Lasseter KC, Chiang ST, Rogers SL, et al. Pharmacokinetics of oxaprozin in patients with hepatic impairment [abstract. Clin Res 1985; 33 (2): 284.

    Google Scholar 

  43. Davis LJ, Kayser SR, Hubsher J, et al. Effect of oxaprozin on the steady-state anticoagulant activity of warfarin. Clin Pharmacokinet 1984; 3: 295–7.

    CAS  Google Scholar 

  44. Halabi A, Linde M, Zeidler H, et al. Double-blind study on the interaction of oxaprozin with metoprolol in hypertensives. Cardiovasc Drugs Ther 1989; 3: 441–3.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. College of Health Science and Department of Pharmacy, The University of Sydney, Sydney, New South Wales, 2006, Australia

    Neal M. Davies

Authors
  1. Neal M. Davies
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Neal M. Davies.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Davies, N.M. Clinical Pharmacokinetics of Oxaprozin. Clin Pharmacokinet 35, 425–436 (1998). https://doi.org/10.2165/00003088-199835060-00002

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00003088-199835060-00002

Keywords

Search

Navigation